As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

Op-ed: By investing in a peer workforce, policymakers can help Latinx communities overcome barriers to accessing quality HIV ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

is a priority for Gilead." The introduction of lenacapavir represents a significant leap forward in HIV prevention strategies. As we await its regulatory approval and broader availability, this ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Health NGO, Right to Care, highlights the urgent need for circumcision among boys aged 15 and older in KwaZulu-Natal to ...